Background Insulin resistance is a critical cause of metabolic dysfunctions. Metabolic
dysfunction is common in patients with cancer and is associated with higher cancer …

Cancer cachexia is a syndrome of progressive weight loss and muscle wasting occurring in
many advanced cancer patients. Cachexia significantly impairs quality of life and increases …

Background Metabolic dysfunction and cachexia are associated with poor cancer prognosis.
With no pharmacological treatments, it is crucial to define the molecular mechanisms …

Background Surgery for urological cancers is associated with high complication rates and
survivors commonly experience fatigue, reduced physical ability and quality of life. High …

Aim To investigate systemic regulators of the cancer‐associated cachexia syndrome (CACS)
in a pre‐clinical model for lung cancer with the goal to identify therapeutic targets for tissue …

Ground-breaking discoveries have established 5′-AMP-activated protein kinase (AMPK) as
a central sensor of metabolic stress in cells and tissues. AMPK is activated through cellular …

Thyroid carcinoma (TC) can be classified as medullary (MTC) and non-medullary (NMTC).
While most TCs are sporadic, familial forms of MTC and NMTC also exist (less than 1% and …

Tumors in dogs and humans share many similar molecular and genetic features,
incentivizing a better understanding of canine neoplasms not only for the purpose of treating …

Background Insulin (INS) resistance and hypoinsulinemia commonly observed in cancer-
carrying, can contribute to cachexia. However, the effects of INS and INS sensitizers, such as …

Background Metabolic dysfunction and cancer cachexia are associated with poor cancer
prognosis, yet the molecular mechanisms causing cancer-induced metabolic dysfunction …